Virogin is dedicated to bringing next-generation immuno-oncology therapeutics to the clinic through our robust pipeline.
Oncolytic Virus (Attenuated & Non-attenuated Viral Backbone）
Transcription & Translation
Dual Regulation (TTDR)
mRNA Vaccines and Therapeutics (Conventional mRNA & Self-amplifying RNA）
*VG161 to be developed for the Greater China market in partnership with CNBG, a Sinopharm subsidiary (Virogin Biotech retains worldwide rights excluding Greater China);
i.t= intratumoral; i.v= intravenous